- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04424108
Hormone Therapy on Serum Ischemia Modified Albumin in Menopausal Women
The Effect of Hormone Therapy on Serum Ischemia Modified Albumin Levels in Surgical Menopausal Women
Women suffer from cardiovascular diseases 10 years later than men, therefore female sex has been considered as a 'protective factor'. However, the risk of cardiovascular disease in women increases rapidly after menopause and the declining levels of endogenous estrogen is thought to be the causative factor. Furthermore, Postmenopausal hormone therapy (HT) decreases the severity and intensity of menopausal symptoms and improves women's quality of life. Until the last 10 years, based on the results of observational studies, postmenopausal HT may protect women against cardiovascular events and decrease the risk of coronary artery disease by 35-50%. However, recent randomized primary and secondary prevention trials did not support the cardioprotective effect of HT.
The aim of this study is to assess the effect of hormone therapy on serum ischemia modified albumin (IMA) levels. Thirty surgical menopausal women who admitted to Karadeniz Technical University, Faculty of Medicine, Department of Obstetrics and Gynecology during 1-year period and diagnosed as menopause and planned to have hormone therapy for menopausal symptoms were enrolled for this prospective study. The serum İMA levels were recorded before and after (3 months, 6 months, 12 months later) hormone treatment (2 mg Estradiol Hemihidrat).
Study Overview
Status
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- accepting consent to participate in the trial and signing the form
- Surgical menopausal women aged 45-55 (having TAH + BSO for benign reasons)
- Presence of vasomotor or menopausal symptoms (moderate to severe);
- no systemic disease or infectious disease in the past 2 weeks
- Not taking any other hormone therapy or medication until postoperative 6th week;
- no contraindications for hormone therapy in routine menopause evaluation;
- Willingness to take hormone therapy
- No smoking.
Exclusion Criteria:
- Any systemic disease presence
- Smoking
- Contraindications for hormone therapy
- Failure to follow-up
- Inability to complete three months of hormone therapy
- quitting hormone therapy for other medical reasons during hormone therapy
- Cases reported as preinvasive and invasive genital tumors as a result of TAH + BSO
- Cases reported as suspicious findings in the mammography report
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measuring serum ischemia-modified albumin (IMA) level
Time Frame: 12 months
|
After collecting all blood, serums were re-dissolved, and serum IMA levels were checked.
IMA level was evaluated by the rapid colorimetric method developed by Barr-Or as an absorbance unit.
For IMA, the results were recorded in the spectrophotometer at appropriate wavelengths, and the results were recorded as absorbance units.
|
12 months
|
Hormone therapy usage
Time Frame: 12 months
|
Estradiol hemihydrate containing preparation 12 boxes in all patients given 1 tablet per day (2 mg / day) was prescribed as.
Patients were recommended to reapply at the 3rd, 6th, and 12th months of treatment following drug use.
|
12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2009/54
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hormone Therapy Induced Morphologic Change
-
Medical University of ViennaRecruitingGender Dysphoria | Hormone Therapy Induced Morphologic ChangeAustria
-
Cairo UniversityUnknownMorphologic Change | Number of Roots
-
Universidade Federal do ParaCompletedTooth Discoloration | Tooth Sensitivity | Morphologic ChangeBrazil
-
Villa dei GeraniUniversity Magna GraeciaCompletedDiabetes Mellitus, Type 2 | Nutritional and Metabolic Diseases | Vascular System Injury | Therapy-Related Morphologic ChangeItaly
-
Ho Young HwangCompletedCoronary Artery Disease | Morphologic ChangeKorea, Republic of
-
Universidad de ZaragozaCompletedCognitive Change | Aging | Randomized Controlled Trial | Occupational Therapy
-
Taipei City HospitalCompletedChemotherapy-Induced ChangeTaiwan
-
Universidade Estadual de Ciências da Saúde de AlagoasUniversity of Sao Paulo; UPECLIN HC FM Botucatu UnespUnknownEffects of Immunosuppressant Therapy | Change of Transit or CirculationBrazil
-
Hasan Kalyoncu UniversityCompletedSubacromial Impingement Syndrome | Morphologic ChangeTurkey
-
Cosmetique Active InternationalCompletedUltraviolet-Induced Change in Normal SkinFrance, Brazil, Poland, Romania